According to the National Center for Biotechnology (NCBI), the human microbiota consists of 10-100 trillion symbiotic microbial cells, which is harbored by each person, this primarily includes bacteria in the gut. The human microbiome consists of the genes these microbial cells harbor. Microbiome projects worldwide have been launched with the goal of understanding the roles that these microbes play and their impacts on human health. They are being studied for the treatment of diseases such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal disorders, central nervous system disorders, and others.
Market Dynamics
Increasing incidence rate of various gut disorders (inflammatory bowel disease (IBD), Crohn’s disease etc.) is expected to increase the growth of the global human microbiome market over the forecast period. For instance, according to a study published in Lancet in October 2019, around 319 (U.S.) cases and around 322 (Europe) cases of Crohn’s disease were reported per 100,000 people. As per the Centers for Disease Control and Prevention’s (CDC) 2018 statistics, an estimated 1.3% of the U.S. adults (accounting for 3 million individuals) were diagnosed with IBD (either Crohn’s disease or ulcerative colitis) in 2015. This showcased a major increase in the incidence rate of IBD from 1999, when 0.9% of the U.S. adults (2 million) were diagnosed with IBD.
Market players are involved in inorganic activities such as collaborations for research and development activities. This is expected to increase the growth of the market over the forecast period. For instance, in 2017, Second Genome, Inc., collaborated with the research institutes i.e., Stanford Cancer Institute, Ruprecht-Karl's-University Heidelberg, Roswell Park Comprehensive Cancer Center, and John Theurer Cancer Center in order to evaluate the effect of gut microbiota on individual response to cancer immunotherapies.
Key features of the study:
- This report provides an in-depth analysis of global human microbiome market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global human microbiome market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP, Evelo Biosciences Inc., Ferring Pharmaceuticals, 4D Pharma Plc., Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., SECOND GENOME THERAPEUTICS, Osel Inc., OxThera AB, Immuron Ltd., AOBiome, Vedanta Biosciences, Inc., Rebiotix Inc., Seres Therapeutics, Inc., Assembly Biosciences, Inc., and Finch Therapeutics Group, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global human microbiome market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the human microbiome market
Detailed Segmentation:
- Global Human Microbiome Market, By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- Global Human Microbiome Market, By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- Global Human Microbiome Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Human Microbiome Market, By Region:
- North America
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- Foods
- Probiotics
- Prebiotics
- Medical Foods
- Fecal Microbiota Transplant (FMT)
- Microbiome Drugs
- Others
- By Disease Indication:
- Clostridium Difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Metabolic Disorders
- Autoimmune Disorders
- Allergic Diseases
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- ENTEROME SA*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Embion Technologies S.A
- IGEN BIOLAB GROUP
- Evelo Biosciences Inc
- Ferring Pharmaceuticals
- 4D Pharma Plc
- Gnubiotics Sciences
- YSOPIA Bioscience
- ViThera Pharmaceuticals Inc.
- SECOND GENOME THERAPEUTICS
- Osel Inc.
- OxThera AB
- Immuron Ltd.
- AOBiome
- Vedanta Biosciences, Inc.
- Rebiotix Inc.
- Seres Therapeutics, Inc.
- Assembly Biosciences, Inc.
- Finch Therapeutics Group, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
